Thalidomide-NH-alkynes is a synthesized E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC HDAC degrader-2.

VU439 is a functionalized photoaffinity ligand of Elexacaftor). VU439 retains the activity of Elexacaftor as a CFTR corrector and can identify SCCPDH as a specific off-target of Elexacaftor through chemoproteomics.

iDeg-3 is a selective molecular glue degrader that targets IDO1. iDeg-3 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 46 nM). iDeg-3 can be used for the researches of cancer, infection and neurological disease, such as melanoma.

iDeg-6 is a selective molecular glue degrader that targets IDO1 with a DC50 of 6.5 nM. iDeg-6 can competitively bind to the heme binding site of apo-IDO1, preventing heme binding and inhibiting the enzymatic reaction that converts tryptophan into kynurenine by IDO1 (IC50 = 1.6 μM). iDeg-6 can be used for the researches of cancer, infection and neurological disease, such as melanoma.

MCB-36 is a VHL-recruiting pan-KRAS PROTAC degrader without affecting KRAS transcription. MCB-36 exhibits minimal effects on HRAS and NRAS protein levels. MCB-36 binds to the GDP-loaded state of G12D, G12C, G12V, and wild-type KRAS with high affinities Kd ≈ 1 pM). MCB-36 decreases p-ERK levels, leading to cell apoptosis. MCB-36 effectively suppress KRASG12C inhibitor-resistant cancer cells and remodel the tumor immune microenvironment. MCB-36 can be used for the study of colorectal cancer and lung cancer.

DDO-4033 is a SPOP inhibitor (IC50 = 16.9 μM, Kd = 15.1 μM). DDO-4033 impairs the malignant migration, invasion, and proliferation of clear cell renal cell carcinoma (ccRCC) cell lines. DDO-4033 disrupts SPOP recruitment to its substrate LATS1, inhibits its polyubiquitination and subsequent degradation, and upregulates LATS1 expression. DDO-4033 has promising antitumor activity and is promising for renal cell carcinoma research.

DEL1187-126-5-80 is a JAK3 inhibitor with IC50s of 52 and 7.9 nM against JAK3 WT in 0 and 60 min. DEL1187-126-5-80 has no activity at all towards the C909S mutant, JAK1, JAK2, and TYK2. DEL1187-126-5-80 can be used for the study of immune-mediated diseases.

(Rac)-Ibrutinib alkyne (Compound 8) is a Btk inhibitor with an IC50 of 0.72 nM. (Rac)-Ibrutinib alkyne can effectively inhibit functions related to the B-cell receptor signaling pathway, with an IC50 of 9 nM for inhibiting Ca flux in Ramos cells. (Rac)-Ibrutinib alkyne can be used in the research of diseases such as rheumatoid arthritis.

L-767685, the ethyl ester prodrug of L-767679), is a non-peptide glycoprotein IIb/IIIa receptor (GPIIb-IIIa receptor) antagonist. L-767679 has a potent anti-platelet aggregation effect. L-767685 can be used for research on antithrombosis.

TBE56, a molecular glue, is a BACH1 degrader, with an EC50 of 44 nM. TBE56 is a weak NRF2 inducer and the biotinylated TBE31. TBE56 interacts and promotes the degradation of BACH1 via a mechanism involving the E3 ligase FBX022. TBE56 reduces intracellular Fe2+ accumulation, ROS generation, and malondialdehyde (MDA) content, while increasing GSH/GSSG ratio and upregulating GPX4 in Prominin-2-overexpressed BMSCs. TBE56 significantly ameliorates intervertebral disc degeneration (IVDD) in puncture-induced SD rat IVDD model. TBE56 can be used for the study of intervertebral disc degeneration (IVDD).

(S,R,S)-AHPC-Me-amide-C4-Br incorporates a VHL ligand for the E3 ubiquitin ligase and a PROTAC linker. (S,R,S)-AHPC-Me-amide-C4-Br can be used to design PROTAC, such as PROTAC ERK5 degrader-1.

Piperidine-azetidine-Br is a PROTAC linker that can be used in the synthesis of PROTACs, such as BY13.

HPK1 ligand 3 is a ligand for target protein for PROTAC that can be used to synthesize PROTAC HPK1 Degrader-4.

WZH-15-125 is a potent ALK inhibitor. WZH-15-125 can effectively overcome drug resistance, especially compound ALK mutations. WZH-15-125 has an IC50 of 101.7 nM for the highly refractory G1202R/L1196M mutation that is resistant to Lorlatinib. WZH-15-125 can be used as a PROTAC target protein ligand to synthesize PROTAC WZH-17-002. WZH-15-125 can be used in the research of non-small cell lung cancer.

ML-220 is a PI3K modulator that can be used for the study of neoplasms and infectious diseases.

(rac)-TBAJ-5307 is the racemate of TBAJ-5307. TBAJ-5307 is a broad spectrum anti-non-tuberculous mycobacteria inhibitor that can target the FO-domain of the engine and preventing rotation and proton-translocation.

Sulfonadyn-47 is a GTP-competitive dynamin I (dynI) inhibitor that targets the active site in the GTPase domain of dynamin I, with IC50 values of 3.5 μM against dynI, 27.3 μM in clathrin-mediated endocytosis (CME) assays, and 12.3 μM in synaptic vesicle endocytosis (SVE) assays. Sulfonadyn-47 increases seizure threshold. Sulfonadyn-47 can be used the study for the seizure.

CH0076989 is a specific CCR3 agonist. CH0076989 activates eosinophils and transfectants expressing both wild-type CCR3 and a CCR1:CCR3 chimaeric receptor lacking the CCR3 amino-terminus. CH0076989 has a direct interaction with the transmembrane helices of CCR3, supported by the complete loss of its activity due to mutations of the residues Y41, Y113 and E287. CH0076989 can be used for the study of inflammation and allergic diseases (such as asthma).

VVD-442 is a covalent RAS-PI3K inhibitor. VVD-442 binds covalently to cysteine 242 in the RAS binding domain of PI3K p110α and blocks RAS/PI3K interaction. VVD-442 can be used cancers like breast cancer research.

Bastadins-5 is a potent stabilizer for the open state of RYR1. Bastadins-5 enhances Ca2+-induced Ca2+ release. Bastadins-5 can be used in research on central nuclear disease and malignant hypothermia.

Zodasiran is a siRNA targeted to ANGPTL3 in the liver.

Zodasiran sodium is a siRNA targeted to ANGPTL3 in the liver.

Zintevir is an antisense oligonucleotide that targets HIV-1 integrase.

Zintevir sodium is an antisense oligonucleotide that targets HIV-1 integrase.

Zilebesiran sodium is a siRNA that reduce hepatic angiotensinogen levels through RNA interference. it is used for the study of mild to moderate Hypertension. Angiotensinogen is the predominant precursor of angiotensin peptides and a key regulator of syste

XQ-P3 sodium is an aptamer that binds to PD-L1. XQ-P3 can inhibit the PD-1/PD-L1 interaction and restore the function of T cells to detect and attack tumor cells.

XQ-2d sodium is an aptamer that targets TfR/CD71. XQ-2d binds to PL45 cells through recognizing CD71 protein.

VR11 aptamer is a DNA-based TNF-α inhibitor with a KD of 7.0 nM. VR11 aptamer prevents TNFα-induced apoptosis and NO production. VR11 aptamer has non-immunogenicity and does not raise immune responses when injected intraperitoneally into C57BL/6 mice model. VR11 aptamer can be used for inflammatory diseases research.

Vortosiran, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.

Vortosiran sodium, a siRNA, is a blood coagulation factor XI synthesis reducer with anticoagulant activity.